This is a 5-year (+30 days) long term follow up study to evaluate the safety of Livercellgram in subject who participated in and completed the Livercellgram Phase 2 trials (refer to ClinicalTrials.gov.Identifier: NCT01875081).
This is a 5-year (+30 days) long term follow up study to evaluate the safety of Livercellgram in subject who participated in and completed the Livercellgram Phase 2 trials (refer to ClinicalTrials.gov.Identifier: NCT01875081). This trial is planned to evaluate the safety of Livercellgram in patients with alcoholic liver cirrhosis. Subjects who signed this follow-up observation informed consent form will participate in a safety assessment (tumor marker test, occurrence of adverse events and serious adverse events, clinical laboratory tests, vital sign, physical examinations.).
Study Type
OBSERVATIONAL
Enrollment
48
Wonju Severance Christian Hospital
Wŏnju, South Korea
Safety Evaluation assessed by Tumor Marker Test, Adverse Events and Serious Adverse Events, Clinical Laboratory Tests, Vital Signs, and Physical Examinations
1. Tumor Marker Test 2. Occurrence of Adverse Events and Serious Adverse Events 3. Clinical Laboratory Tests 4. Vital Sign 5. Physical Examinations
Time frame: 5-year(+30 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.